Revolution Medicines officer sells 4,302 RVMD shares

Revolution Medicines, Inc. officer Stephen Michael Kelsey reported an open-market sale of 4,302 shares of Common Stock at 99.4804 per share.

Rhea-AI Filing Summary

Revolution Medicines, Inc. officer Stephen Michael Kelsey reported an open-market sale of 4,302 shares of Common Stock at 99.4804 per share. The transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations upon vesting of restricted stock units. After this sale, he directly owns 295,398 shares, which includes 84,250 restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 4,302 shares

Net Sell 1 txn

Insider Kelsey Stephen Michael

Role See Remarks

Sold 4,302 shs ($428K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,302	$99.4804	$428K

Holdings After Transaction: Common Stock — 295,398 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
2. F2. Includes 84,250 RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Revolution Medicines (RVMD) report for Stephen Michael Kelsey?

Revolution Medicines reported that officer Stephen Michael Kelsey sold 4,302 shares of Common Stock at 99.4804 per share. After the transaction, he directly holds 295,398 shares, which the filing notes includes 84,250 restricted stock units.

Was the RVMD insider sale by Stephen Michael Kelsey under a Rule 10b5-1 plan?

Yes. The sale was executed pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023. The filing explains this plan was established to satisfy Kelsey’s tax withholding obligations upon vesting of restricted stock units after July 15, 2023.

How many Revolution Medicines shares does Stephen Michael Kelsey hold after this Form 4 transaction?

Following the reported sale, Stephen Michael Kelsey directly owns 295,398 shares of Revolution Medicines Common Stock. The filing specifies that this figure includes 84,250 restricted stock units, which represent share-based awards that may settle in common shares upon vesting.

What price did Stephen Michael Kelsey receive per share in the RVMD sale?

The filing shows an average price of 99.4804 per share for the 4,302 shares sold. This reflects the transaction price reported for the open-market sale and is used to calculate the total value of the disposition disclosed in the Form 4.

Why did Stephen Michael Kelsey sell RVMD shares in this transaction?

According to the footnote, the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units. The transaction followed a Rule 10b5-1 instruction letter adopted on May 31, 2023, indicating it was pre-arranged rather than opportunistic.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 06:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelsey Stephen Michael

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		4,302	D	$99.4804	295,398(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 84,250 RSUs.

Remarks:

President, Research and Development

	/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)